Loading…
VYNE Therapeutics Inc is projected to rise to $28.78 by 2027, a +1% move from its current price of $28.56. VYNE is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/4/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 5 | $25.08 | $28.58 | $32.58 | +0.07% |
| Aug 6 | $23.77 | $28.60 | $34.42 | +0.14% |
| Aug 7 | $22.82 | $28.62 | $35.90 | +0.22% |
| Aug 8 | $22.05 | $28.64 | $37.21 | +0.29% |
| Aug 9 | $21.39 | $28.66 | $38.41 | +0.36% |
| Aug 10 | $20.82 | $28.68 | $39.52 | +0.43% |
| Aug 11 | $20.30 | $28.70 | $40.58 | +0.51% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $20.30 | $28.70 | $40.58 | +0.51% |
| Week 2 | $17.68 | $28.85 | $47.07 | +1.01% |
| Week 3 | $15.92 | $29.00 | $52.82 | +1.53% |
| Week 4 | $14.58 | $29.14 | $58.24 | +2.04% |
| Week 5 | $13.51 | $29.29 | $63.52 | +2.56% |
| Week 6 | $12.61 | $29.44 | $68.74 | +3.07% |
| Week 7 | $11.84 | $29.59 | $73.95 | +3.60% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
VYNE Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing therapies to treat chronic inflammatory and immune-mediated conditions. Its lead program is repibresib gel (VYN201), a topically administered small molecule pan-bromodomain and extra-terminal (BET) inhibitor soft drug designed to address diseases involving multiple inflammatory cell signaling pathways with low systemic exposure.
The company also develops VYN202, a BD2-selective oral small molecule BET inhibitor in Phase 1b trial for the acute control and chronic management of immune-mediated inflammatory conditions. VYNE Therapeutics Inc. was formerly known as Menlo Therapeutics Inc.
and changed its name to VYNE Therapeutics Inc. in September 2020. The company was founded in 2003 and is based in Stewartsville, New Jersey.
VYNE Therapeutics Inc. (VYNE) currently trades at $28.56 per share, and has a market capitalization of $19.07M. Its rank is 4709 in market listings.
The thirty-day technical picture is bullish, with RSI14 at 40, SMA50 at $34.08 and SMA200 at $28.15. Key support and resistance levels are reported at $25.45 and $46.15, respectively, and the thirty-day range spans from $19.03 to $42.86.
Forecasts show a path of growth through 2050, starting from 2026 with an average around $28.56 and rising across years to 2050. Notable checkpoints include 2030 with an average of $36.47 and a maximum near $63.19, 2040 with an average of $163.53 and a maximum near $358.72, and 2050 with an average of $251.65 and a maximum near $578.80. The longer-run outlook implies sizable upside potential, with ROIs reaching 781.1% by 2050.
A major floor 98.0% below — a decisive break under it would weaken the trend.
The nearest floor, 97.8% below — buyers have tended to step in here.
The nearest ceiling, 61.7% above — a clean break opens room to run.
A major ceiling 61.7% above — clearing it would confirm fresh momentum.
Key VYNE support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of VYNE market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $11.20 | Buy | $15.32 | Buy |
| MA 10 | $5.98 | Buy | $9.39 | Buy |
| MA 20 | $3.32 | Buy | $5.46 | Buy |
| MA 50 | $1.73 | Buy | $2.70 | Buy |
| MA 100 | $1.17 | Buy | $1.68 | Buy |
| MA 200 | $0.8242 | Buy | $1.22 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 99.83 | Sell |
| Stoch RSI (14) | 100.00 | Sell |
| CCI (20) | 350.51 | Buy |
| Williams %R (14) | 0.00 | Info |
| MACD (12,26,9) | 2.64 | Buy |
| ROC (12) | 4045.09 | Buy |
| Bollinger %B (20,2) | 1.29 | Sell |
| Stochastic %K (14) | 100.00 | Sell |
| TRIX (15) | 18.84 | Buy |
| Awesome (5,34) | 8.98 | Buy |
| Ultimate (7,14,28) | 99.87 | Sell |
| Momentum (10) | 27.20 | Buy |
| Aroon Osc (25) | 100.00 | Buy |
| Hull MA (9) | 19.12 | Buy |
| ADX (14) | 39.23 | Buy |
| ATR (14) | 1.82 | Info |
The 30-day technical picture is bullish. RSI14 is 40, indicating modest momentum with a constructive bias. The 50-day simple moving average sits at $34.08 while the 200-day simple moving average is at $28.15, framing a near-term backdrop supportive of upside moves.
Support is at $25.45 and resistance at $46.15, with the 30-day price range between $19.03 and $42.86.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $0.5536 | $28.56 | $42.48 | 0% | Neutral | |
| $20.97 | $28.78 | $42.68 | +1% | Neutral | |
| $23.87 | $34.83 | $55.12 | +22% | Bullish | |
| $21.62 | $33.25 | $55.29 | +16% | Neutral | |
| $17.91 | $28.89 | $50.02 | +1% | Neutral | |
| $25.07 | $42.27 | $75.79 | +48% | Bullish | |
| $30.20 | $53.11 | $98.19 | +86% | Bullish | |
| $32.55 | $59.62 | $113.32 | +109% | Bullish | |
| $32.98 | $62.85 | $122.49 | +120% | Bullish | |
| $26.40 | $52.29 | $104.29 | +83% | Bullish | |
| $44.72 | $99.38 | $217.93 | +248% | Bullish | |
| $65.26 | $145.02 | $333.54 | +408% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $0.5536 | $28.56 | $37.14 | +0.00% |
| September 2026 | $24.42 | $29.68 | $37.64 | +3.92% |
| October 2026 | $24.75 | $30.50 | $39.47 | +2.77% |
| November 2026 | $25.96 | $32.36 | $42.56 | +6.10% |
| December 2026 | $25.27 | $31.84 | $42.48 | -1.62% |
Click any year to see its month-by-month VYNE forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
By 2026, VYNE could reach as high as $42.48, with a base case around $28.56 and support toward $0.5536 — roughly 0% from $28.56. A consolidation phase looks the most probable path here.
Expect VYNE to range from $20.97 to $42.68 through 2027. The $28.78 average target implies a +1% move from current prices. That is up +1% on the projected 2026 average. Price action looks broadly range-bound.
The VYNE price prediction for 2028 points to an average of $34.83 (low $23.87, high $55.12) — a potential gain of +22% on today's $28.56. Buyers look set to stay in control over this stretch.
In 2029, VYNE is projected to trade between $21.62 and $55.29, averaging $33.25 — a potential gain of +16% from today's $28.56. That is -5% versus the projected 2028 average. Price action looks broadly range-bound.
VYNE Therapeutics Inc's 2030 outlook centres on $28.89, within a $17.91 to $50.02 range. That is -13% versus the projected 2029 average. That marks a +1% change versus current levels. A consolidation phase looks the most probable path here.
By 2031, VYNE could reach as high as $75.79, with a base case around $42.27 and support toward $25.07 — roughly +48% from $28.56. Momentum favours further upside here.
Expect VYNE to range from $30.20 to $98.19 through 2032. The $53.11 average target implies a +86% move from current prices. That is up +26% on the projected 2031 average. Buyers look set to stay in control over this stretch.
The VYNE price prediction for 2033 points to an average of $59.62 (low $32.55, high $113.32) — a potential gain of +109% on today's $28.56. Momentum favours further upside here.
In 2034, VYNE is projected to trade between $32.98 and $122.49, averaging $62.85 — a potential gain of +120% from today's $28.56. That is up +5% on the projected 2033 average. Buyers look set to stay in control over this stretch.
VYNE Therapeutics Inc's 2035 outlook centres on $52.29, within a $26.40 to $104.29 range. That is -17% versus the projected 2034 average. That marks a +83% change versus current levels. Momentum favours further upside here.
By 2040, VYNE could reach as high as $217.93, with a base case around $99.38 and support toward $44.72 — roughly +248% from $28.56. Buyers look set to stay in control over this stretch.
Expect VYNE to range from $65.26 to $333.54 through 2050. The $145.02 average target implies a +408% move from current prices. That is up +46% on the projected 2040 average. Momentum favours further upside here.
Investing $1,000 in VYNE today (≈ 35.014006 VYNE) could be worth
$5,077.58
+$4,077.58 (+408%) by 2050 · US Dollar
Based on the average projected VYNE price of $145.02 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in VYNEwould be worth at today's price.
$1,000 invested in VYNE on Jul 28, 2025 (≈ 689.65515 VYNE) would be worth
$19,696.55
+$18,696.55 (+1869.7%) today · 19.70× · US Dollar
Based on a VYNE entry price of $1.45 vs. today's $28.56.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $0.808 | $35,346.53 | +3434.7% |
| 1 month ago | $0.648 | $44,074.07 | +4307.4% |
| 3 months ago | $0.64 | $44,625 | +4362.5% |
| 6 months ago | $0.565 | $50,548.67 | +4954.9% |
| 1 year ago | $1.45 | $19,696.55 | +1869.7% |
| All time (5.0y) ago | $47.16 | $605.6 | -39.4% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our VYNE forecast.
Our base-case forecast reaches $57.00 around 2033.
Implied market cap at $57.00: $38.06M
The multi-year forecast envisions a sustained uptrend, with the average price slipping into the mid- to high-40s in the near term and then climbing through the 2030s and beyond. In 2030, the average price is $36.47 with a maximum near $63.19 and a 27.7% ROI. By 2040, the average rises to $163.53 and the max to $358.72, with a 472.6% ROI.
In 2050, the average is projected at $251.65 and the max at $578.80, yielding a 781.1% ROI. The forecast remains bullish in the long run, though these are estimates and not guarantees. Given the year-by-year progression, the asset is expected to continue exhibiting higher average levels into the 2030s, 2040s, and beyond, with substantial upside risk and uncertainty inherent in long-horizon projections.
Tap a question to reveal the answer.
The 2030 forecast shows an average of $36.47 with a min of $22.59 and a max of $63.19, and a ROI of 27.7%. The sentiment is bullish for that year.
The forecast points to a path of growth with a 2026 average of $28.56 and a 2050 average of $251.65, including a 2050 ROI of 781.1%. These are estimates, not guarantees, and should be weighed with other considerations.
Yes. The 2031 max is $100.54, and subsequent years show higher max values such as $132.66 in 2032, $159.41 in 2033, and $177.66 in 2034.
For 2026, the min is $25.45, the average is $28.56, and the max is $43.29.
The 2050 forecast shows an average of $251.65, a min of $113.24, and a max of $578.80, with a ROI of 781.1% and bullish sentiment.
VYNE Therapeutics Inc Community Discussion
0Share your VYNE Therapeutics Inc price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.